[Impact of Helicobacter pylori eradication on morphological changes in gastric mucosa].
The purpose of the study was to examine gastric mucosal morphological changes in patients with gastroduodenal pathology after eradication therapy for Helicobacter pylori (H. pylori). A hundred and thirty-eight patients (40 females and 98 males) were examined. Of them, there were 122 patients with duodenal peptic ulcer, 8 with gastric peptic ulcer, 5 with erosive gastritis, 2 with chronic atrophic antral gastritis, and 1 with non-atrophic gastritis. Two months and a year after therapy, manifestations of gastric mucosal atrophy, the degree of inflammation, and its activity significantly diminished in patients with complete H. pylori eradication. Positive changes were observed mainly in the antral portion of the stomach. In patients with partial eradication, chronic inflammation and its activity became less. Two months and a year following therapy, positive changes in the gastric mucosa were absent in patients without H. pylori eradication.
Pimanov
S I
SI
0000-0001-6067-3600
Vitebsk State Medical University, 210009, Vitebsk, Belarus
Makarenko
E V
EV
Vitebsk State Medical University, 210009, Vitebsk, Belarus
Krylov
Iu V
IuV
Vitebsk Regional Bureau of Pathology, 210037, Vitebsk, Belarus
Matveenko
M E
ME
Vitebsk State Medical University, 210009, Vitebsk, Belarus
Malashenko
S V
SV
Vitebsk Regional Bureau of Pathology, 210037, Vitebsk, Belarus
Bondarenko
V M
VM
Vitebsk State Medical University, 210009, Vitebsk, Belarus
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000382:microbiology / Q000473:pathology*; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D005757:Gastritis, Atrophic / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors; D013276:Stomach Ulcer / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*
D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors